So the farce that is the US drug approvals theatre continues as now Regeneron pulls out of testing advanced suffering COIVD-19 patients due to safety concerns:
Bar Dexamethasone and proning, and the results therein are not unequivocal, after 8 months we still have nothing to treat advanced sufferers and bear in mind 90% of mortalities have incidents of ARDS associated. What a sorry state of affairs the world is in.
What a shame Mt Sinai and the NIH have been so tardy too during the biggest medical crisis in modern history. REM-L might be the only genuine treatment answer out there and we are stuck here waiting for recruitment, despite the US now having 100,000 cases a day.
MSB Price at posting:
$3.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)